Updates of CSCO guidelines for colorectal cancer version 2025.
作者信息
Lu Demin, Dong Caixia, Wang Kailai, Ye Chenyang, Chen Liubo, Yuan Ying, Hu Hanguang
机构信息
Department of Medical Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, China), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Zhejiang Provincial Clinical Research Center for Cancer, Hangzhou 310009, China.
出版信息
Chin J Cancer Res. 2025 Jun 30;37(3):297-302. doi: 10.21147/j.issn.1000-9604.2025.03.01.
Abstract
摘要
相似文献
1
Updates of CSCO guidelines for colorectal cancer version 2025.《2025年版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南》更新内容
Chin J Cancer Res. 2025 Jun 30;37(3):297-302. doi: 10.21147/j.issn.1000-9604.2025.03.01.
2
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2019版》相对于2018版的更新内容。
Chin J Cancer Res. 2019 Jun;31(3):423-425. doi: 10.21147/j.issn.1000-9604.2019.03.03.
3
Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2020》相对于2019版的更新内容。
Chin J Cancer Res. 2020 Jun;32(3):403-407. doi: 10.21147/j.issn.1000-9604.2020.03.11.
4
Application of Case-Based Learning Combined with PDCA in the Training of Grassroot Surgeons for the Updates in the CSCO Guidelines for the Diagnosis and Treatment of Breast (2023).基于案例的学习结合PDCA在基层外科医生CSCO乳腺癌诊疗指南（2023年版）更新培训中的应用
Niger J Clin Pract. 2025 May 1;28(5):666-671. doi: 10.4103/njcp.njcp_161_24. Epub 2025 Jun 4.
5
CSCO guidelines for colorectal cancer version 2023: Updates and insights.《2023版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南：更新与见解》
Chin J Cancer Res. 2023 Jun 30;35(3):233-238. doi: 10.21147/j.issn.1000-9604.2023.03.02.
6
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.《2024版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南：更新与讨论》
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
7
CSCO guidelines for colorectal cancer version 2022: Updates and discussions.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南2022版：更新与讨论》
Chin J Cancer Res. 2022 Apr 30;34(2):67-70. doi: 10.21147/j.issn.1000-9604.2022.02.01.
8
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.中国临床肿瘤学会（CSCO）：《中国结直肠癌诊疗规范（2024年版）》
Cancer Commun (Lond). 2025 Mar;45(3):332-379. doi: 10.1002/cac2.12639. Epub 2024 Dec 31.
9
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.中国临床肿瘤学会（CSCO）乳腺癌诊疗指南2022
Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022.
10
Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020.《中国临床肿瘤学会（CSCO）结直肠癌诊疗指南》2021年版相较于2020年版的更新内容。
Chin J Cancer Res. 2021 Jun 30;33(3):302-307. doi: 10.21147/j.issn.1000-9604.2021.03.02.
本文引用的文献
1
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.纳武利尤单抗联合伊匹木单抗对比纳武利尤单抗治疗微卫星高度不稳定转移性结直肠癌（CheckMate 8HW）：一项随机、开放标签的3期试验
Lancet. 2025 Feb 1;405(10476):383-395. doi: 10.1016/S0140-6736(24)02848-4. Epub 2025 Jan 25.
2
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹木单抗治疗微卫星不稳定高转移性结直肠癌。
N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.
3
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response.新辅助免疫疗法治疗错配修复缺陷型和微卫星稳定型结直肠癌：治疗策略和可能的反应生物标志物。
Nat Rev Clin Oncol. 2024 Dec;21(12):839-851. doi: 10.1038/s41571-024-00943-6. Epub 2024 Sep 24.
4
Cancer incidence and mortality in China, 2022.2022年中国癌症发病率与死亡率
J Natl Cancer Cent. 2024 Feb 2;4(1):47-53. doi: 10.1016/j.jncc.2024.01.006. eCollection 2024 Mar.
5
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.《2024版中国临床肿瘤学会（CSCO）结直肠癌诊疗指南：更新与讨论》
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
6
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.新辅助短程放疗联合卡瑞利珠单抗和化疗治疗局部进展期直肠癌（UNION）：一项多中心随机 III 期临床试验的早期结果。
Ann Oncol. 2024 Oct;35(10):882-891. doi: 10.1016/j.annonc.2024.06.015. Epub 2024 Jul 2.
7
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).基于免疫治疗的总新辅助治疗在熟练错配修复或微卫星稳定局部晚期直肠癌中的随机 II 期试验（TORCH）。
J Clin Oncol. 2024 Oct;42(28):3308-3318. doi: 10.1200/JCO.23.02261. Epub 2024 Jul 1.
8
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.卡瑞利珠单抗联合阿帕替尼新辅助治疗局部晚期微卫星高度不稳定或错配修复缺陷型结直肠癌（NEOCAP）：一项单臂、开放标签、Ⅱ期研究。
Lancet Oncol. 2024 Jul;25(7):843-852. doi: 10.1016/S1470-2045(24)00203-1. Epub 2024 Jun 6.
9
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
10
Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.帕博利珠单抗新辅助治疗高风险微卫星稳定型直肠腺癌
JAMA Surg. 2024 May 1;159(5):529-537. doi: 10.1001/jamasurg.2023.7996.
Zotero 插件